litlas
Log inCreate account

Gary R. Lichtenstein

Active 1996–2025

Also published as
Gary R Lichtenstein · Gary R. Lichtenstein§
111
Papers
30,344
Citations
80
h-index
108
i10-index

Citations

Citations per year for Gary R. Lichtenstein1973: 1 citations1991: 3 citations1993: 2 citations1998: 1 citations1999: 5 citations2000: 17 citations2001: 31 citations2002: 42 citations2003: 88 citations2004: 109 citations2005: 159 citations2006: 201 citations2007: 244 citations2008: 277 citations2009: 246 citations2010: 303 citations2011: 313 citations2012: 277 citations2013: 354 citations2014: 314 citations2015: 314 citations2016: 245 citations2017: 250 citations2018: 256 citations2019: 858 citations2020: 900 citations2021: 650 citations2022: 494 citations2023: 387 citations2024: 640 citations2025: 301 citations2026: 8 citations1974–1990: no citations, so these years are not shown1992: no citations, so this year is not shown1994–1997: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,227 citing papers, 21.8% of this breakdownUnited Kingdom: 782 citing papers, 7.7% of this breakdownCanada: 733 citing papers, 7.2% of this breakdownItaly: 623 citing papers, 6.1% of this breakdownFrance: 532 citing papers, 5.2% of this breakdownGermany: 487 citing papers, 4.8% of this breakdownBelgium: 412 citing papers, 4% of this breakdownChina: 402 citing papers, 3.9% of this breakdownNetherlands: 392 citing papers, 3.9% of this breakdownSpain: 339 citing papers, 3.3% of this breakdownJapan: 312 citing papers, 3.1% of this breakdownAustralia: 245 citing papers, 2.4% of this breakdown
0%21.8%Other 26.6%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology64.4%
  • Medicine25.6%
  • Immunology and Microbiology5.3%
  • Neuroscience1.1%
  • Nursing0.9%
  • Pharmacology, Toxicology and Pharmaceutics0.7%
  • Other2%

Topics

  • Inflammatory Bowel Disease24.3%
  • Microscopic Colitis9.1%
  • Rheumatoid Arthritis Research and Therapies5.1%
  • Autoimmune and Inflammatory Disorders3.8%
  • Biosimilars and Bioanalytical Methods3%
  • Gut microbiota and health2.5%
  • Other52.2%

Coauthors

All papers

Open in search
  1. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

    Authors: Paul Rutgeerts, William J. Sandborn, Brian G. Feagan, Walter Reinisch, Allan Olson, Jewel Johanns, Suzanne Travers, Daniel Rachmilewitz, Stephen B. Hanauer, Gary R. Lichtenstein, Willem J.S. de Villiers, Daniel H. Present, Bruce E. Sands, Jean‐Frédéric Colombel - New England Journal of Medicine 2005 cited by 3,883

  2. ACG Clinical Guideline: Management of Crohn's Disease in Adults

    Authors: Gary R. Lichtenstein, Edward V. Loftus, Kim L. Isaacs, Miguel Regueiro, Lauren B. Gerson, Bruce E. Sands - The American Journal of Gastroenterology 2018 cited by 1,406

  3. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

    Authors: Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein, Lloyd Mayer, Stefan Schreiber, Jean‐Frédéric Colombel, Daniel Rachmilewitz, Douglas C. Wolf, Allan Olson, Weihang Bao, Paul Rutgeerts - The Lancet 2002 cited by 4,163

  4. Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis

    Authors: James D. Lewis, Shaokun Chuai, Lisa Nessel, Gary R. Lichtenstein, Faten Aberra, Jonas H. Ellenberg - Inflammatory Bowel Diseases 2008 cited by 952

  5. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

    Authors: Simon Travis, Dan Schnell, Piotr Krzeski, María T. Abreu, Douglas G. Altman, Jean–Frédéric Colombel, Brian G. Feagan, Stephen B. Hanauer, Marc Lémann, Gary R. Lichtenstein, Phillippe R Marteau, Walter Reinisch, Bruce E. Sands, Bruce Yacyshyn, Christian A. Bernhardt, Jean‐Yves Mary, William J. Sandborn - Gut 2011 cited by 626

  6. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

    Authors: Laurent Peyrin‐Biroulet, Jessica R. Allegretti, David T. Rubin, Brian Bressler, Matthew Germinaro, Kuan‐Hsiang Gary Huang, Nicole Shipitofsky, Hongyan Zhang, Rebbecca Wilson, Chenglong Han, Brian G. Feagan, William J. Sandborn, Julián Panés, Tadakazu Hisamatsu, Gary R. Lichtenstein, Bruce E. Sands, Axel Dignaß, О. Аbrahamovych, Halyna Afanasieva, Lilia Aitova, Engin Altıntaşž, Romain Altwegg, П. С. Андреев, Kazuki Aomatsu, Monika Augustyn, Paola Balestrieri, Jakob Begun, Luciana Soledad Brunatto, Diego Bulgheroni, Elena Bunkova, Mercedes Cabello, Qian Cao, Flavio Caprioli, Rute Cerqueira, Baili Chen, Chou‐Chen Chen, Chou-Pin Chen, Cheng‐Tang Chiu, Chang Hwan Choi, Michele Cicala, Olena Datsenko, Pieter Dewint, Eugeni Domènech, Joris Dutré, George Duvall, J. C. Fernández, Rafał Filip, Ronald Fogel, Sharyle Fowler, Toshimitsu Fujii, Masayuki Fukata, Yohei Furumoto, Antonio Gasbarrini, Beata Gawdis-Wojnarska, Cyrielle Gilletta, Paolo Gionchetti, Eran Goldin, Oleksandr Golovchenko, Maciej Gonciarz, Can Gönen, Gaston Gonzalez Segura, Oleksii Gridnyev, T Gyökeres, Xavier Hébuterne, Charlotte Hedin, Per M. Hellström, Ida Hilmi, Ivo Horný, Gyula Horvat, Namiko Hoshi, Luděk Hrdlička, Shunji Ishihara, Olha Ivanishyn, Byung Ik Jang, Odery Junior, Takashi Kagaya, Shuji Kanmura, Marina Karakina, Nakai Katsuhiko, Jarosław Kierkuś, Hyo Jong Kim, Tae-Oh Kim, Young‐Ho Kim, G Kiss, Jochen Klaus, D Kleczkowski, Maria Kłopocka, Taku Kobayashi, Iwona Kobielusz‐Gembala, Ja Seol Koo, Adam Kopoń, Tetiana Kravchenko, Masatoshi Kudo, Kwang An Kwon, Paula Lago, David Laharie, Ian C. Lawrance, Jarosław Leszczyszyn, Yan Li, Milan Lukáš and 64 more - Gastroenterology 2023 cited by 92

  7. Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis

    Authors: Jean‐Frédéric Colombel, Paul Rutgeerts, Walter Reinisch, Dirk Eßer, Yanxin Wang, Yinghua Lang, Colleen Marano, Richard Strauß, B.J. Oddens, Brian G. Feagan, Stephen B. Hanauer, Gary R. Lichtenstein, Daniel H. Present, Bruce E. Sands, William J. Sandborn - Gastroenterology 2011 cited by 919

  8. Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity

    Authors: Simon Travis, Dan Schnell, Piotr Krzeski, María T. Abreu, Douglas G. Altman, Jean–Frédéric Colombel, Brian G. Feagan, Stephen B. Hanauer, Gary R. Lichtenstein, Philippe Marteau, Walter Reinisch, Bruce E. Sands, Bruce Yacyshyn, Patrick Schnell, Christian A. Bernhardt, Jean–Yves Mary, William J. Sandborn - Gastroenterology 2013 cited by 446

  9. Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry

    Authors: Gary R. Lichtenstein, Brian G. Feagan, Russell D. Cohen, Bruce Salzberg, Robert H. Diamond, Samiyeh Price, Wayne Langholff, Anil Londhe, William J. Sandborn - The American Journal of Gastroenterology 2012 cited by 796

  10. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease

    Authors: Francis A. Farraye, Gil Melmed, Gary R. Lichtenstein, Sunanda V. Kane - The American Journal of Gastroenterology 2017 cited by 473

  11. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

    Authors: David T. Rubin, Jessica R. Allegretti, Julián Panés, Nicole Shipitofsky, Shadi Yarandi, Kuan‐Hsiang Gary Huang, Matthew Germinaro, Rebbecca Wilson, Hongyan Zhang, Jewel Johanns, Brian G. Feagan, Tadakazu Hisamatsu, Gary R. Lichtenstein, Brian Bressler, Laurent Peyrin‐Biroulet, Bruce E Sands, Axel Dignaß, О. Аbrahamovych, Niazy Abu-farsakh, Halyna Afanasieva, Hale Akpınar, Houssam Al Kharrat, Engin Altıntaşž, Romain Altwegg, П. С. Андреев, Kazuki Aomatsu, Hiroshi Araki, Marjorie Argollo, Federico Ariel, Alessandro Armuzzi, Toshifumi Ashida, Monika Augustyn, Guy Aumais, Martín Azum, Filip Baert, Jozef Baláž, Domingo Balderramo, Jakob Begun, Temenuzhka Berova, Lore Billiauws, Antonio Blanco, Martin Bortlík, Fabrizio Bossa, Elena Bunkova, Mercedes Cabello, Qian Cao, Flavio Caprioli, Rute Cerqueira, Karen A. Chachu, Patrick Chamouard, Chunxiao Chen, Yan Chen, Baili Chen, Dongfeng Chen, Hong Chen, Youxiang Chen, Chou‐Chen Chen, Jaehee Cheon, Minhu Chen, Cheng-Tang Chiu, Chang‐Hwan Choi, Elizabeth Chow, Michele Cicala, Aderson Cintra, Wit Danilkiewicz, Olena Datsenko, Gert De Hertogh, Julio De María, L Medina, Deliang Liu, Pierre Desreumaux, Pieter Dewint, Shigang Ding, Glen Doherty, Raina Draganova, Joris Dutré, George Duvall, Laurence J. Egan, Julien Fahed, Lars Fechner, Miroslav Fedurco, Aykut Ferhat Celik, J. C. Fernández, Rafał Filip, Sigal Fishman, Cristina Flores, Ronald Fogel, Sharyle Fowler, Carlos Fernando de Magalhães Francesconi, Toshimitsu Fujii, Mikihiro Fujiya, Masayuki Fukata, Seiichiro Fukuhara, Yohei Furumoto, G Kiss, Waldemar Gachowski, Xiang Gao, Antonio Gasbarrini, Beata Gawdis-Wojnarska, Daniel R. Gaya and 248 more - The Lancet 2024 cited by 83

  12. Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Azathioprine and 6-Mercaptopurine: A Meta-analysis

    Authors: David Kotlyar, James D. Lewis, Laurent Beaugerie, Ann Tierney, Colleen Brensinger, Javier P. Gisbert, Edward V. Loftus, Laurent Peyrin‐Biroulet, Wojciech Błoński, Manuel Van Domselaar, María Chaparro, Sandipani Sandilya, Meenakshi Bewtra, Florian Beigel, Livia Biancone, Gary R. Lichtenstein - Clinical Gastroenterology and Hepatology 2014 cited by 406

  13. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease

    Authors: Paul Rutgeerts, Brian G. Feagan, Gary R. Lichtenstein, Lloyd Mayer, Stefan Schreiber, Jean‐Frédéric Colombel, Daniel Rachmilewitz, Douglas C. Wolf, Allan Olson, Weihang Bao, Stephen B. Hanauer - Gastroenterology 2004 cited by 948

  14. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease

    Authors: Paul Rutgeerts, Robert H. Diamond, Mohan Bala, Allan Olson, Gary R. Lichtenstein, Weihang Bao, Kamlesh B. Patel, Douglas C. Wolf, Michael Safdi, Jean‐Frédéric Colombel, Bret A. Lashner, Stephen B. Hanauer - Gastrointestinal Endoscopy 2006 cited by 549

  15. Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry

    Authors: Gary R. Lichtenstein, Brian G. Feagan, Russell D. Cohen, Bruce Salzberg, Robert H. Diamond, Donny M. Chen, Michelle L. Pritchard, William J. Sandborn - Clinical Gastroenterology and Hepatology 2006 cited by 907

  16. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients

    Authors: Faten Aberra, James D. Lewis, David J. Hass, John L. Rombeau, Benjamin Osborne, Gary R. Lichtenstein - Gastroenterology 2003 cited by 348

  17. Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study

    Authors: Bruce E. Sands, William J. Sandborn, Brian G. Feagan, Gary R. Lichtenstein, Hongyan Zhang, Richard Strauß, Philippe Szapary, Jewel Johanns, Julián Panés, Séverine Vermeire, Christopher D. O’Brien, Zijiang Yang, Kirk Bertelsen, Colleen Marano, Peficitinib-UC Study Group - Journal of Crohn s and Colitis 2018 cited by 115

  18. Lifetime Economic Burden of Crohn’s Disease and Ulcerative Colitis by Age at Diagnosis

    Authors: Gary R. Lichtenstein, Ahva Shahabi, Seth A. Seabury, Darius Lakdawalla, Oliver Díaz Espinosa, Sarah Green, Michelle Brauer, Robert N. Baldassano - Clinical Gastroenterology and Hepatology 2019 cited by 107

  19. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial

    Authors: David T. Rubin, Russell D. Cohen, William J. Sandborn, Gary R. Lichtenstein, Jeffrey Axler, Robert H. Riddell, Cindy Zhu, Andrew C. Barrett, Enoch Bortey, William P. Forbes - Journal of Crohn s and Colitis 2017 cited by 75

  20. A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease

    Authors: David Kotlyar, Mark T. Osterman, Robert H. Diamond, David L. Porter, Wojciech Błoński, Mariusz A. Wasik, Sami Sampat, Manuel Mendizábal, Ming Lin, Gary R. Lichtenstein - Clinical Gastroenterology and Hepatology 2010 cited by 471

  21. Rosiglitazone for Active Ulcerative Colitis: A Randomized Placebo-Controlled Trial

    Authors: James D. Lewis, Gary R. Lichtenstein, Julius J. Deren, Bruce E. Sands, Stephen B. Hanauer, Jeffrey A. Katz, Bret A. Lashner, Daniel H. Present, Shaokun Chuai, Jonas H. Ellenberg, Lisa Nessel, Gary D. Wu - Gastroenterology 2008 cited by 226

  22. Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis

    Authors: David T. Rubin, Walter Reinisch, Thomas Greuter, Paulo Gustavo Kotze, Marcia R.T. Pinheiro, Rajiv Mundayat, Eric S. Maller, Marc Fellmann, Nervin Lawendy, Irene Modesto, Stephan R. Vavricka, Gary R. Lichtenstein - Therapeutic Advances in Gastroenterology 2021 cited by 35

  23. 759 THE EFFICACY AND SAFETY OF GUSELKUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR MAINTENANCE STUDY

    Authors: David T. Rubin, Jessica R. Allegretti, Julián Panés, Nicole Shipitofsky, Shadi Yarandi, Kuan‐Hsiang Gary Huang, Matthew Germinaro, Rebbecca Wilson, Hongyan Zhang, Brian G. Feagan, Tadakazu Hisamatsu, Gary R. Lichtenstein, Brian Bressler, Laurent Peyrin‐Biroulet, Bruce E. Sands, Axel Dignaß - Gastroenterology 2024 cited by 14

  24. [American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease].

    Authors: Gary R. Lichtenstein, Maria T Sbreu, Russell D. Cohen, William J. Tremaine - Gastroenterology 2006 cited by 419